The treatment of breast cancer has always been a technical exercise in the prevention of local recurrence after surgery or radiotherapy. It was considered that recurrence was a failure in treatment, and that it determined the rapidity of dissemination and influenced the survival of the patient. Many trials, conducted in the majority of cases by surgeons, have failed to show a significant bias in any of the treatment methods used. In fact, to quote Sir Hedley Atkins: 'Our recent studies of breast cancer have made such progress that we now realize that none of us knows how to treat it' (personal communication) .
At the present time the role of the surgeon in the treatment of breast cancer is clear cut. He makes the diagnosis, initiates the locoregional treatment, and supervises the fol1ow up. The initial treatment by surgery is the prevention of local recurrence only. The survival in time of the patient is determined by the presence or absence of dissemination, and when this is present by the rate of growth of either soft tissue or osseous deposits. When the disease becomes disseminated he may continue treatment or refer the patient for radiotherapy or chemotherapy.
Some 40 years ago, disappointed with the results of the surgical treatment of breast cancer, particularly in the more advanced cases, combined clinics were advocated by a number of clinicians, particularly Sir Stanford Cade and Professor Sir David Smithers. Here the patient was seen initial1y by the surgeon and the radiotherapist. and treatment was planned in relation to the stage of advancement of the disease. This was a significant advance but unfortunately these clinics were confined to the larger centres where a consultant radiotherapist was available. In most district hospitals the surgeon alone had to plan treatment. The fol1ow-up period was undertaken in the combined clinic by the surgeon and radiotherapist. In those cases with local recurrence or dissemination, palliative radiotherapy, hormonal chemotherapy or ablative endocrine surgery were advised. This method of planning and executing treatment remained unchanged until the advent of cytotoxic chemotherapy. In many centres now both adjuvant and therapeutic chemotherapy are given by the existing staff, that is to say the surgeon and radiotherapist. But more recently in some centres. the services of a medical oncologist o141-{)768/80/120837-{)2/$01.00/0 experienced in the use of cytotoxic drugs have become available.
Is there any way in which a change in this traditional management will be of advantage to the patient, and should there be a reappraisal of the role of the surgeon? It is not easy to make any progress in diagnosis or therapy because of our limited knowledge of the aetiology of breast cancer. However, some improvement might be expected if the following were achieved:
(I) Improved data recording.
(2) Availability of cytology, mammography and isotope scanning with appropriate consultant advice.
(3) Assessment relating to prognosis based on the histology and the receptor status of the primary lesion and the regional nodes. (4) The services of a medical oncologist experienced in the administration of cytotoxic chemotherapy. (5) A mastectomy counsellor and a nurse specialist.
A simple and effective method would be the establishment of more breast clinics. There is no doubt that the treatment of breast cancer is now multidisciplinary and the surgeon should be part of the team -not working in isolation. This may not be as impracticable as it seems since already in many hospitals most of the patients with breast cancer are referred to one surgeon who has shown a particular interest in or aptitude for treatment. The surgeon may not be the first consultant to see the patient in the breast clinic. This would depend on the way in which the clinic was run. There must be accurate data recording at the initial examination by the surgeon and perhaps a computer terminal should be available in the clinic. An agreed questionnaire having been worked out, it is only necessary to answer the questions which are shown on the screen. The surgeon should make the initial diagnosis. This is important because the current negative biopsy rate in all hospitals is high, at least 2.26 to I (Royal Marsden Hospital, London). A reduction in the number of unnecessary biopsies would help to release hospital beds and save money for the National Health Service.
The surgeon should have readily available reliable histology of Trucut biopsies and fine needle aspiration cytology. A good mammographic facility is essential. When the diagnosis and clinical staging have been determined, it is customary to screen the patient for evidence of © 1980 The Royal Society of Medicine 838. Journal of the Royal Society of Medicine Volume 73 December 1980 disseminated disease by chest X-ray, isotope scanning and full blood investigations. Only a small number of patients will be found to have evidence of dissemination, but it is still an essential part of clinical staging (Forrest et al. 1980 , Coombes et al. 1980 . At the present time the role of the surgeon in treatment is limited. He will remove the tumour to confirm the diagnosis. Immediate histological examination is essential and with the diagnosis established a plan of treatment must now be made. The surgeon has only one objective, to treat the patient in such a way that he will give the maximum chance of freedom from local recurrence both in the breast and in the regional lymph nodes. If the surgeon considers that removal of the breast will give the best and perhaps the only chance of preventing local recurrence, then every effort should be made to carry out an anatomically adequate excision. The axilla must be dissected since not only will involved nodes be removed but the pathological stage will then be known. In all other cases where the surgeon decides that the removal of the breast will not affect either the length of survival or the incidence of local recurrence, limited surgery is indicated. Mutilation without hope has no place in the treatment of breast cancer.
When it is considered that there is even the slightest possibility of a mastectomy the surgeon must discuss the implications of the operation with the patient. Until recently the support of the patient has often been neglected.
The surgeon should always have available the help of a mastectomy counsellor. A nurse specialist attached to the clinic will advise the patient about the types of prosthesis available and the suitability of clothes and swimsuits.
After the initial treatment by surgery, the further management of the patient should be discussed with the medical oncologist and the radiotherapist since the problem now is the prevention of local recurrence and dissemination. However, routine radiotherapy or adjuvant cytotoxic therapy to node-positive cases may not increase survival. There are many factors which need to be considered in the planning of prophylactic or adjuvant therapy: for example, the histology of the tumour, the presence or absence of vascular invasion or lymphatic permeation and, perhaps most significant, the oestrogen receptor status (Nealon et al. 1979 ,Sampat et al. 1977 ,Lee 1979 . It is here that the medical oncologist and the radiotherapist have perhaps a more important role to play than the surgeon. The role of the surgeon in locally advanced disease, both with or without evidence of dissemination, is limited only to establishing the diagnosis, and the plan of treatment should be made by consultation with other members of the unit. o141-fJ768j120838-fJ3j$01.00/0
In the follow up period it has always been a tradition that the patient should remain under the care of the surgeon and indeed the patient always expects to see 'her surgeon'. This has often been impractical because of the sheer number of cases. The combined breast clinic may provide a satisfactory solution. It will allow the surgeon to supervise the follow up with the other members of the team.
Thus, although the surgeon should continue to play a major part in the management of the patient with breast cancer, he should be given the opportunity to work with a team and likewise should give them the opportunity to work with him.
W P Greening Consulting Surgeon Royal Marsden Hospital. London
Drug trials in rheumatoid arthritis
The practice of rheumatology has become flooded in the last few years by the arrival of large numbers of compounds which are capable of reducing inflammation and taking away the pain of arthritis. These drugs are largely symptomatic in their mode of action in that they do not interfere with the underlying disease process. Disease-modifying agents with slow onset of action that may not be anti-inflammatory in conventional tests have been available. Historically, the first of these was gold and, more recently, penicillamine has appeared to rival this compound. Both these drugs are frequently toxic, gold causing proteinuria, blood abnormalities and skin rashes, while the use of penicillamine leads to a myriad of reversible side effects which include virtually all systems of the body. A good example of this is dermatomyositis, described by Fernandes et al. (1977) and confirmed by the case report in
